1. Home
  2. MDWD vs UIS Comparison

MDWD vs UIS Comparison

Compare MDWD & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.80

Market Cap

230.7M

Sector

Health Care

ML Signal

HOLD

Logo Unisys Corporation New

UIS

Unisys Corporation New

HOLD

Current Price

$2.86

Market Cap

260.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDWD
UIS
Founded
2000
1942
Country
Israel
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
230.7M
260.2M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
MDWD
UIS
Price
$18.80
$2.86
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$37.50
$5.88
AVG Volume (30 Days)
96.8K
686.2K
Earning Date
11-20-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,932,000.00
$1,921,000,000.00
Revenue This Year
$15.89
N/A
Revenue Next Year
$25.33
$0.20
P/E Ratio
N/A
N/A
Revenue Growth
6.15
N/A
52 Week Low
$14.14
$2.37
52 Week High
$22.51
$7.54

Technical Indicators

Market Signals
Indicator
MDWD
UIS
Relative Strength Index (RSI) 55.27 49.08
Support Level $18.71 $2.75
Resistance Level $19.40 $3.10
Average True Range (ATR) 0.63 0.11
MACD 0.14 0.06
Stochastic Oscillator 65.02 60.17

Price Performance

Historical Comparison
MDWD
UIS

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.

Share on Social Networks: